FDA Deems Longeveron's HLHS Trial Non-Pivotal, Citing Insufficient Primary Endpoint
LGVN sits 61% above its 52-week low of $0.475 on light trading volume (0.1× avg).
Summary
The FDA has informed Longeveron that the primary endpoint of right ventricle ejection fraction (RVEF) in its ELPIS II Phase 2b clinical trial for Hypoplastic Left Heart Syndrome (HLHS) is not considered an appropriate endpoint to demonstrate efficacy. Consequently, the FDA no longer refers to the ELPIS II trial as pivotal, a significant reversal from previous discussions in 2024. This development introduces substantial uncertainty regarding the path to market for Longeveron's lead investigational product, laromestrocel, as a pivotal trial is typically required for regulatory approval. This news follows closely on the heels of Longeveron seeking shareholder approval for a reverse stock split to maintain its Nasdaq listing, underscoring the company's precarious financial position. Investors will now closely watch the anticipated top-line results in August 2026 and subsequent discussions with the FDA for any potential path forward, which may necessitate additional trials.
At the time of this announcement, LGVN was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.7M. The 52-week trading range was $0.48 to $1.80. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.